Javascript must be enabled to continue!
From chemistry to genomics: A concise history of the porphyrias
View through CrossRef
AbstractWe describe developments in understanding of the porphyrias associated with each step in the haem biosynthesis pathway and the role of individuals whose contributions led to major advances over the past 150 years. The first case of erythropoietic porphyria was reported in 1870, and the first with acute porphyria in 1889. Photosensitisation by porphyrin was confirmed by Meyer‐Betz, who self‐injected haematoporphyrin. Günther classified porphyrias into haematoporphyria acuta, acuta toxica, congenita and chronica. This was revised by Waldenström into porphyria congenita, acuta and cutanea tarda, with the latter describing those with late‐onset skin lesions. Waldenström was the first to recognise porphobilinogen's association with acute porphyria, although its structure was not solved until 1953. Hans Fischer was awarded the Nobel prize in 1930 for solving the structure of porphyrins and the synthesis of haemin. After 1945, research by several groups elucidated the pathway of haem biosynthesis and its negative feedback regulation by haem. By 1961, following the work of Watson, Schmid, Rimington, Goldberg, Dean, Magnus and others, aided by the availability of modern techniques of porphyrin separation, six of the porphyrias were identified and classified as erythropoietic or hepatic. The seventh, 5‐aminolaevulinate dehydratase deficiency porphyria, was described by Doss in 1979. The discovery of increased hepatic 5‐aminolaevulinate synthase activity in acute porphyria led to development of haematin as a treatment for acute attacks. By 2000, all the haem biosynthesis genes were cloned, sequenced and assigned to chromosomes and disease‐specific mutations identified in all inherited porphyrias. These advances have allowed definitive family studies and development of new treatments.
Title: From chemistry to genomics: A concise history of the porphyrias
Description:
AbstractWe describe developments in understanding of the porphyrias associated with each step in the haem biosynthesis pathway and the role of individuals whose contributions led to major advances over the past 150 years.
The first case of erythropoietic porphyria was reported in 1870, and the first with acute porphyria in 1889.
Photosensitisation by porphyrin was confirmed by Meyer‐Betz, who self‐injected haematoporphyrin.
Günther classified porphyrias into haematoporphyria acuta, acuta toxica, congenita and chronica.
This was revised by Waldenström into porphyria congenita, acuta and cutanea tarda, with the latter describing those with late‐onset skin lesions.
Waldenström was the first to recognise porphobilinogen's association with acute porphyria, although its structure was not solved until 1953.
Hans Fischer was awarded the Nobel prize in 1930 for solving the structure of porphyrins and the synthesis of haemin.
After 1945, research by several groups elucidated the pathway of haem biosynthesis and its negative feedback regulation by haem.
By 1961, following the work of Watson, Schmid, Rimington, Goldberg, Dean, Magnus and others, aided by the availability of modern techniques of porphyrin separation, six of the porphyrias were identified and classified as erythropoietic or hepatic.
The seventh, 5‐aminolaevulinate dehydratase deficiency porphyria, was described by Doss in 1979.
The discovery of increased hepatic 5‐aminolaevulinate synthase activity in acute porphyria led to development of haematin as a treatment for acute attacks.
By 2000, all the haem biosynthesis genes were cloned, sequenced and assigned to chromosomes and disease‐specific mutations identified in all inherited porphyrias.
These advances have allowed definitive family studies and development of new treatments.
Related Results
The porphyrias: advances in diagnosis and treatment
The porphyrias: advances in diagnosis and treatment
Abstract
The inborn errors of heme biosynthesis, the porphyrias, are 8 genetically distinct metabolic disorders that can be classified as “acute hepatic,” “hepatic c...
The porphyrias: advances in diagnosis and treatment
The porphyrias: advances in diagnosis and treatment
Abstract
The inborn errors of heme biosynthesis, the porphyrias, are 8 genetically distinct metabolic disorders that can be classified as “acute hepatic,” “hepatic c...
The porphyrias
The porphyrias
Abstract
The porphyrias are a remarkable family of metabolic disorders characterized biochemically by overproduction of haem precursors, principally in the liver ...
Anesthetic implications in porphyrias
Anesthetic implications in porphyrias
The porphyrias are a group of disorders related to deficient heme biosynthesis, caused by malfunction of certain enzymes in the synthesis pathway. Erythropoietic porphyrias present...
Genomics and society: four scenarios for 2015
Genomics and society: four scenarios for 2015
This paper develops four alternative scenarios depicting possible futures for genomics applications within a broader social context. The scenarios integrate forecasts for future ge...
The Porphyrias
The Porphyrias
The porphyrias are metabolic diseases caused by altered activities of enzymes in the heme biosynthetic pathway. Signs and symptoms of porphyria result from overproduction and accum...
Molecular mechanisms of dominant expression in porphyria
Molecular mechanisms of dominant expression in porphyria
SummarySummary:#Partial deficiency of enzymes in the haem synthetic pathway gives rise to a group of seven inherited metabolic disorders, the porphyrias. Each deficiency is associa...
Genomics education for medical specialists: case-based specialty workshops and blended learning
Genomics education for medical specialists: case-based specialty workshops and blended learning
Aim: To develop and evaluate genomics education programs for health professionals to expedite the translation of genomics into healthcare. Methods: Our co-design team of genetic s...

